Some parts of the portal may cause error messages or display incorrectly due to the transition to a new provider of trading data

RCUS - Arcus Biosciences Inc


Close
17.12
-0.210   -1.227%

Share volume: 436,621
Last Updated: Fri 30 Aug 2024 10:00:03 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology): 0.21%

PREVIOUS CLOSE
CHG
CHG%

$17.33
-0.21
-1.21%
5D - 1M - 3M - 1Y - 3Y - 5Y - 10Y - 15Y
Fundamental analysis
13%
Profitability 0%
Dept financing 14%
Liquidity 73%
Performance 11%
Company vs Stock growth
vs
Performance
5 Days
-4.94%
1 Month
8.49%
3 Months
14.67%
6 Months
-10.60%
1 Year
-14.78%
2 Year
-28.93%
Key data
Stock price
$17.12
P/E Ratio 
-6.29
DAY RANGE
$16.64 - $17.58
EPS 
-$3.04
52 WEEK RANGE
$12.95 - $22.68
52 WEEK CHANGE
-$0.19
MARKET CAP 
1.565 B
YIELD 
N/A
SHARES OUTSTANDING 
91.428 M
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
11/05/2024
BETA 
1.67
PUBLIC FLOAT 
$0
AVERAGE 10 VOLUME 
$525,716
AVERAGE 30 VOLUME 
$649,785
Company detail
CEO:
Region: US
Website: arcusbio.com
Employees: 511
IPO year: -
Issue type: Common Stock
Market: NYSE
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

arcus biosciences is an exciting young company founded on a vision of creating new cancer therapeutics through the utilization of emerging insights in immunology. arcus was formed in 2015 by a group of seasoned researchers from the biotechnology and pharmaceutical industries and is located in the san francisco bay area, in the heart of the world’s largest biotechnology research hub. unlike many other organizations, we view the drug discovery process as one that requires equal parts of technology and art, science and elegance, not as a commodity that can be outsourced. for this reason, we have assembled and are continuing to build an internal team of uniquely qualified individuals with extraordinary knowledge, skills and drive. arcus is rapidly establishing a portfolio of novel therapeutics encompassing both small molecules and biologics that target various facets of the immune system implicated in pathology or modulation of the cellular processes of cancer. these new drugs will then be

Recent news